Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Lintuzumab-Ac225 Exerts Mutation Agnostic Antileukemic Activity in Preclinical Models of AML

Amanda Chin, Rubin Jiao, Kevin J.H. Allen, Jason Li, Mary Chen, Madhuri Vusirikala, Avinash Desai, Le-Cun Xu, Patrik Brodin, Monideepa Roy, Mackenzie Malo, Denis Beckford-Vera, Ekaterina Dadachova, Helen Kotanides

Blood (2024) 144 (Supplement 1): 5801.

https://doi.org/10.1182/blood-2024-204282

Published: 2024

Journal Articles

Outcome of Patients with TP53 Mutated Relapsed/Refractory AML with Lintuzumab-Ac225 in Combination with CLAG-M Following Venetoclax Plus Hypomethylating Agent Therapy

Sameem Abedin, Guru Subramanian Guru Murthy, Mehdi Hamadani, Laura C. Michaelis, Karen-Sue Carlson, Lyndsey Runaas, Katelyn Gauger, Avinash Desai, Mary Chen, Patrik Brodin, Kate L Li, Mojisola Rotibi, Umar Sayeed, Alexandra M. Harrington, Ehab L. Atallah

Blood (2024) 144 (Supplement 1): 4258.

https://doi.org/10.1182/blood-2024-201559

Published: 2024

Journal Articles

Lintuzumab-Ac225, a CD33-Directed Antibody Radiotherapy, Targets AML in a Mutation Agnostic Manner

Amanda Chin, Rubin Jiao, Kevin J.H. Allen, Jason Li, Mary Chen, Madhuri Vusirikala, Le-Cun Xu, Patrik Brodin, Monideepa Roy, Mackenzie Malo, William Van der Touw, Ekaterina Dadachova, Denis Beckford-Vera, Helen Kotanides

Blood (2023) 142 (Supplement 1): 5750.

https://doi.org/10.1182/blood-2023-187498

Published: 2023

Journal Articles

Updated Results from Phase 1 Study of Targeted Radiotherapy with Lintuzumab-Ac225 in Combination with Venetoclax in Relapsed/Refractory AML

Gail J. Roboz, Laura E. Finn, Johnnie J. Orozco, Mohamed Hegazi, Avinash Desai, Mary Chen, Gary J. Schiller

Blood (2023) 142 (Supplement 1): 1539.

https://doi.org/10.1182/blood-2023-178802

Published: 2023